A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
NCT03283085
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
557
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Ulcerative Colitis
Interventions
DRUG:
25 mg Ontamalimab
DRUG:
75 mg Ontamalimab
Sponsor
Shire